Printer Friendly
The Free Library
14,528,975 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Ensemble Discovery and Roche Initiate Research Collaboration to Apply New Diagnostic Technology to Optimize Cancer Therapy.


Collaboration will enable analysis of critical drug target family in patient cancer biopsies and selection of appropriate therapy

CAMBRIDGE, Mass. -- Ensemble Discovery Corporation today announced the initiation of a collaboration with Roche of Basel, Switzerland to apply Ensemble's proprietary diagnostic technology to the optimization of selection of cancer therapy. The collaboration will apply this technology (known as DNA-Programmed Chemistry(TM)) to analyze combinations of members of the Epidermal Growth Factor Receptor This article is about a cell suface receptor. For estimated measure of kidney function (eGFR), see Glomerular filtration rate.
The epidermal growth factor receptor
 (EGFR EGFR Epidermal Growth Factor Receptor (a kinase enzyme)
EGFR Estimated Glomerular Filtration Rate
) family that are present in cancer tissues. The goal of the collaborative project is to create a sensitive test to detect receptor dimers in human cancer tissue samples.

The potential clinical benefit of the test is to select cancer patients who are most likely to respond to a particular therapy targeted against a member of the EGFR family. The particular combinations of EGFR dimers present in the cancer are believed to be a significant factor in determining the efficacy of drugs targeting the EGFR family. The Ensemble test will correlate the EGFR family dimer dimer /di·mer/ (di´mer)
1. a compound formed by combination of two identical molecules.

2. a capsomer having two structural subunits.


di·mer
n.
1.
 pattern with efficacy of particular anti-cancer drugs in order to improve therapy selection based on an individual's molecular constitution.

The EGFR family includes some of the most widely targeted molecules in modern cancer medicine. There are six drugs against this family on the market and several more in clinical trials. However, in each case, the drugs show activity in a subset of the patients in which they are currently indicated and the mechanisms of this partial efficacy are not well understood. Ensemble's test will be initially used to monitor breast cancer patients but could also have utility in other solid tumors such as colon and lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. .

"We are very pleased to enter into this collaboration with Roche," said David J David J. Haskins (b. April 24, 1957, in Northampton, England) is a British alternative rock musician. He was the bassist for the seminal gothic rock band Bauhaus. Life and work . Livingston, Ph.D., Senior Vice President, and head of the biodetection program at Ensemble Discovery. "The opportunity to collaborate with a global leader in both pharmaceuticals and diagnostics as well as pioneering anti-EGFR therapies, offers a unique opportunity to apply the collective expertise and experience for the development of our tests in cancer diagnosis."

"Roche is one of the world's leading cancer companies with commitment to both the drug and diagnostic sides of cancer healthcare," said Laurence Reid, Chief Business Officer of Ensemble Discovery. "Ensemble is committed to deploying its DNA-Programmed Chemistry technology for the development of diagnostic tests that will enable the optimal use of the important anti-EGFR family of drugs in cancer patients."

Ensemble is developing a suite of diagnostic services diagnostic services,
n.pl the imaging and laboratory capabilities available for determining the cause of an illness.
 and kits, based on DPC DPC Department of Premier and Cabinet (Victoria, Australia)
DPC Dutch Power Cows
DPC Deferred Procedure Calls (Microsoft Windows NT 4.
(TM), to analyze EGFR family dimers and other cancer markers for use in cancer diagnosis and drug selection. The company will partner with leading pharmaceutical and diagnostic companies to deliver its diagnostic products and position them relative to ongoing drug development.

About Ensemble Discovery Corporation

Based in Cambridge, MA, Ensemble Discovery Corporation is harnessing a fundamentally new approach to controlling chemical reactivity to develop novel classes of therapeutics and bioassays. Ensemble Discovery is deploying DNA-Programmed Chemistry (DPC), which is based on the groundbreaking work of Professor David Liu David Liu is a Taiwanese figure skater. He represented Taiwan at three Olympic Games: the 1998 Winter Olympics, where he placed 27th; 1992 Winter Olympics where he placed 17th; and the 1988 Winter Olympics, where he placed and 25th.  of Harvard University and Howard Hughes Medical Institute Howard Hughes Medical Institute, (HHMI), nonprofit medical research organization founded in 1953 by Howard Hughes and largly funded from proceeds of the 1984–85 sale of Hughes Aircraft. Headquartered in Chevy Chase, Md. . In its drug discovery programs, Ensemble uses DPC to generate Programmed Macrocycles(TM) as drug candidates for pharmaceutically challenging targets. In its diagnostic programs, Ensemble uses DPC to control the generation of detection signals in response to the presence of specific molecular events underlying human diseases. DPC-based assays are particularly adept at the detection of dimeric molecules such as growth factor receptors on cell surfaces.

About the EGFR Family

The Epidermal Epidermal
Referring to the thin outermost layer of the skin, itself made up of several layers, that covers and protects the underlying dermis (skin).

Mentioned in: Antiangiogenic Therapy, Histiocytosis X


epidermal
 Growth Factory Receptor (EGFR) family is one of the best characterized families of cancer-associated proteins. Members of the family are known to be involved in the etiology of breast, lung and colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States.  and their pathologic and biochemical mechanisms have been widely studied since their discovery and isolation in the 1980s.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 30, 2007
Words:633
Previous Article:Scottrade Marks Milestone with Opening of 306th Nationwide Branch Office in Canton, Ohio.
Next Article:EIA Reorganization Gives ECA Opportunity to Expand Programs.
Topics:



Related Articles
Lanxess builds rubber research facility.(Acquisitions, expansions)
Pequiven, Petroquimica de Venezuela, the Venezuelan state-owned company, and Braskem, a South American manufacturer of thermoplastic resins, have...
The University of Buffalo's (www.buffalo.edu) Center for Integrated Waste Management has been awarded $1.8 million by Empire State Development to...
Rebuilding in-house capabilities.
AIDS initiative signs first lease at bioscience center.
Tennis star Pete Sampras to play celebrity match at Kennedy Funding Invitational.(TRANSCRIPT)
New Jersey NAIOP presents annual real estate awards.
Embracing change: Kaiser Permanente has instituted IT asset management programs that exceed its environmental standards while extending equipment...
Battle fatigue: five years into the sex abuse crisis, some Catholics are growing weary, while others are cautiously optimistic.
Panasonic Develops Advanced Low-range Sound Reproduction Technology for Compact Speakers.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles